1.Activated Protein C Anticoagulant System Dysfunction and Thrombophilia in Asia.
Naotaka HAMASAKI ; Hiroyuki KUMA ; Hiroko TSUDA
Annals of Laboratory Medicine 2013;33(1):8-13
Thrombophilia that is common among Caucasians is caused by genetic polymorphisms of coagulation factor V Leiden (R506Q) and prothrombin G20210A. Unlike that in Caucasians, thrombophilia that is common in the Japanese and Chinese involve dysfunction of the activated protein C (APC) anticoagulant system caused by abnormal protein S and protein C molecules. Approximately 50% of Japanese and Chinese individuals who develop venous thrombosis have reduced activities of protein S. The abnormal sites causing the protein S molecule abnormalities are distributed throughout the protein S gene, PROS1. One of the most common abnormalities is protein S Tokushima (K155E), which accounts for about 30% of the protein S molecule abnormalities in the Japanese. Whether APC dysfunction occurs in other Asian countries is an important aspect of mapping thrombophilia among Asians. International surveys using an accurate assay system are needed to determine this.
Asian Continental Ancestry Group
;
Blood Coagulation
;
Blood Proteins/genetics/metabolism
;
Humans
;
Protein C/genetics/*metabolism
;
Protein S/chemistry/genetics/metabolism
;
Thrombophilia/epidemiology/*etiology
;
Venous Thrombosis/etiology/genetics
2.Effects of HMGB-1 Overexpression on Cell-Cycle Progression in MCF-7 Cells.
Sarah YOON ; Jin Young LEE ; Byung Koo YOON ; Duk Soo BAE ; Doo Seok CHOI
Journal of Korean Medical Science 2004;19(3):321-326
High mobility group-1 (HMGB-1) enhances the DNA interactions and possesses a transcriptional activation potential for several families of sequence-specific transcriptional activators. In order to examine the effect of HMGB-1 on the cell cycle progression in MCF-7 cells, the HMGB-1 expression vector was transfected into synchronized MCF-7 cells, and the effect of HMGB-1 overexpression on the cell cycle was examined. The HMGB-1 protein level in the transfected cells increased 4.87-fold compared to the non-transfected cells. There were few changes in the cell cycle phase distribution after HMGB-1 overexpression in the MCF-7 cells. Following the estrogen treatment, the cell cycle progressed in both the HMGB-1 overexpressed MCF-7 and the mock-treated cells. However, a larger proportion of HMGB-1 overexpressing MCF-7 cells progressed to the either S or G2 phase than the mock-treated cells. The mRNA levels of the cell cycle regulators changed after being treated with estrogen in both the HMGB-1 overexpressing MCF-7 and the mock-treated cells, but the changes in the expression level of the cell cycle regulator genes were more prominent in the HMGB-1 overexpressing MCF-7 cells than in the mock-treated cells. In conclusion, HMGB-1 overexpression itself does not alter the MCF-7 cell cycle progression, but the addition of estrogen to the HMGB-1 overexpressing MCF-7 cells appears to accelerate the cell cycle progression.
Blotting, Western
;
Cell Cycle
;
Cell Line, Tumor
;
Densitometry
;
Estrogens/metabolism
;
G2 Phase
;
Genetic Vectors
;
HMGB1 Protein/*biosynthesis
;
Human
;
Kinetics
;
Oligonucleotides/chemistry
;
Plasmids/metabolism
;
Protein Structure, Tertiary
;
RNA, Messenger/metabolism
;
Reverse Transcriptase Polymerase Chain Reaction
;
S Phase
;
Support, Non-U.S. Gov't
;
Time Factors
;
Trans-Activation (Genetics)
;
Transfection